Nyxoah (NASDAQ:NYXH) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Nyxoah (NASDAQ:NYXH) in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a $17.00 price target on the stock.

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price objective on shares of Nyxoah in a report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Nyxoah has a consensus rating of “Buy” and a consensus target price of $17.00.

Nyxoah Stock Performance

Shares of NYXH stock opened at $8.00 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95. Nyxoah has a 12 month low of $4.00 and a 12 month high of $20.00. The company’s fifty day simple moving average is $8.86 and its 200-day simple moving average is $8.53.

Institutional Trading of Nyxoah

An institutional investor recently bought a new position in Nyxoah stock. Kovack Advisors Inc. bought a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,000 shares of the company’s stock, valued at approximately $96,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.